352 material Form 8-K filings that 310 companies we cover made with the SEC in August 2024, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Agilysys acquired all equity of Book4Time, a spa management software provider, for $150 million in cash, subject to post-closing adjustments. The company funded the deal with cash on hand and a $50 million draw on a new $75 million revolving credit facility with Bank of America as agent. The filing does not report Book4Time's financial results, so shareholders cannot yet assess the deal's effect on revenue or profit from this document.
Purchase price of $150 million in cash, subject to post-closing adjustments; the filing cites an approximate nine times revenue multiple
$50 million drawn on a $75 million revolving credit facility dated August 16, 2024, with a $25 million possible increase; revolver matures in three years
Initial interest margin of 1.625% over SOFR; covenants include minimum 3.00 to 1 interest coverage and leverage below 3.50 to 1.00
Company will discuss any impact on fiscal 2025 guidance on its fiscal 2025 second quarter earnings call in October 2024
Gates Industrial priced an underwritten secondary offering of 20,000,000 ordinary shares held by Blackstone-affiliated selling stockholders, with an option for 3,000,000 more that was exercised in full. The company receives none of the offering proceeds, but it is repurchasing $125 million of its own shares from Citigroup as part of the offering, which matters to shareholders as a direct buyback alongside the sale.
Offering of 20,000,000 ordinary shares by Blackstone-affiliated selling stockholders priced August 15, 2024
Underwriters' 3,000,000-share option exercised in full on August 16, 2024; closing expected August 21, 2024
Company will not receive offering proceeds but will repurchase $125 million of shares from Citigroup Global Markets at the Underwriters' offering price, totaling 7,539,203 shares
Thomas G. Pitstick appointed President, Americas, effective August 16, 2024, with no change to his compensation
Bio-Rad Laboratories appointed Jonathan P. DiVincenzo, formerly an executive at Labcorp, as President and Chief Operating Officer, effective September 9, 2024, replacing Andrew Last, who retires September 5, 2024. CEO Norman Schwartz keeps his role as Chief Executive Officer and Chairman and gives up the title of President.
DiVincenzo's offer letter provides a $665,000 annual base salary and a 2024 target cash bonus of 100% of eligible earnings.
Equity and sign-on terms include restricted stock units valued at $2,500,000 within sixty days of hire and a $1.3 million sign-on bonus payable by February 15, 2025.
DiVincenzo was most recently Executive Vice President and President, Central Laboratories & International at Labcorp from May 2023 to August 2024.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.